ResMed's earnings call highlighted strong financial performance with significant revenue and gross margin growth, increased dividends, and share buyback plans. The company's strategic focus on digital health, AI, and operational efficiency was emphasized. However, concerns about regulatory changes and currency impacts were noted. Overall, the positive achievements outweigh the challenges.

Company Guidance -

Q1 2026

During the Q4 Fiscal Year 2025 earnings call, ResMed reported a 10% year-over-year increase in revenue, achieving $1.35 billion, with a significant expansion of 230 basis points in gross margin. The company emphasized its strategic acquisitions, including Somnoware, Ectosense, and VirtuOx, to enhance its digital health ecosystem and improve patient care pathways. ResMed's free cash flow for the fiscal year was $1.7 billion, allowing flexibility for investments and shareholder returns, including $610 million in dividends and share repurchases. Looking forward, the company aims for further gross margin improvements within the range of 61% to 63% for fiscal year 2026, driven by procurement efficiencies and logistics improvements. ResMed remains committed to its 2030 goal of improving the lives of over 500 million people, with ongoing investments in research and development, operational excellence, and innovative solutions in sleep and respiratory care.

Strong Revenue Growth

ResMed achieved a 10% year-over-year reported revenue growth and 9% in constant currency terms for the fourth quarter of Fiscal Year 2025.

Gross Margin Expansion

The company reported a 230 basis points year-over-year and 150 basis points sequential improvement in gross margin, reaching 61.4% in the quarter.

Free Cash Flow

ResMed reported a free cash flow of $1.7 billion for Fiscal Year 2025, providing significant flexibility for investments and returns to shareholders.

Dividend and Share Buyback Increase

The Board authorized a 13% increase in the quarterly dividend for FY 2026 and plans to increase share buyback to $150 million per quarter.

Operational Excellence and Investment

Continued investment in R&D and SG&A, with an emphasis on digital health and AI technologies, contributing to robust product innovation.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AU:RMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2026 (Q1)	0.39 / -	0.337	―	―	―
Jul 31, 2025	2025 (Q4)	0.39 / 0.39	0.319	22.60% (+0.07)	―	―
Apr 23, 2025	2025 (Q3)	0.36 / 0.36	0.327	11.27% (+0.04)	―	―
Jan 30, 2025	2025 (Q2)	0.36 / 0.37	0.288	29.26% (+0.08)	―	―
Oct 24, 2024	2025 (Q1)	0.32 / 0.34	0.251	34.15% (+0.09)	―	―
Aug 01, 2024	2024 (Q4)	0.32 / 0.32	0.245	30.00% (+0.07)	―	―
Apr 25, 2024	2024 (Q3)	0.30 / 0.33	0.258	26.79% (+0.07)	―	―
Jan 24, 2024	2024 (Q2)	0.27 / 0.29	0.254	13.25% (+0.03)	―	―
Oct 26, 2023	2024 (Q1)	0.25 / 0.25	0.231	8.61% (+0.02)	―	―
Aug 03, 2023	2023 (Q4)	0.26 / 0.25	0.228	7.38% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AU:RMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	AU$42.45	AU$42.88	+1.01%
Apr 23, 2025	AU$33.18	AU$36.00	+8.50%
Jan 30, 2025	AU$40.32	AU$40.00	-0.79%
Oct 24, 2024	AU$35.39	AU$37.48	+5.91%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) report earnings?

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time?

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock?

The P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is N/A.

What is AU:RMD EPS forecast?

AU:RMD EPS forecast for the fiscal quarter 2026 (Q1) is 0.39.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing